Clinical trials: Olfaction
Bacterial Vaginoses
Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV
- Trial name
- NCT03937869
- Testing
- Secnidazole
- Where
- 9 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lupin Research Inc
Congenital Cytomegalovirus Infection
Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
CMV lesions were found in the olfactory system of children with congenital CMV infection but no study has hitherto examined the impact of congenital CMV infection on olfaction.
- Trial name
- INFECSMELL (NCT02782988)
- Testing
- olfactory tests, otoacoustic emissions (OAE)
- Where
- 2 sites in France
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Parkinson Disease
Role of Nasal Dysbiosis in Parkinson Disease
Olfactory dysfunction is frequent in Parkinson Disease (PD) and may be present years before the motor symptoms appear. The early olfactory dysfunction could result from environmental factors acting through the nasal cavity such…
- Trial name
- SMELLPARK (NCT04249245)
- Testing
- Nasal Swab
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Coronavirus Infection, Severe Acute Respiratory Syndrome
Study of the Pathogenesis of Olfactory Disorders in COVID-19
This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, Sars-CoV2
- Trial name
- COVIDSMELL (NCT04366934)
- Testing
- Nasal swab, Taste and olfactory function evaluation
- Where
- 2 sites in France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands Observing Progression With Neurons Study
The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
- Trial name
- CROWN-I (NCT07611396)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Crownlands
Parkinson's Disease
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive…
- Trial name
- THOR201 (NCT03541356)
- Testing
- L-dopa 35 mg, L-dopa 70mg, L-dopa 140 mg
- Where
- 5 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Impel Pharmaceuticals
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Mild Cognitive Impairment, Early Alzheimer's Disease
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
The purpose of this study is to determine whether daily treatment with this new treatment approach, called COT would be effective in protecting the memory and brain regions of people who are already showing signs of memory loss.
- Conditions
- Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
- Trial name
- NCT05122598
- Testing
- COT
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Evon Medics LLC
Migraine Headache
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
A Phase I clinical trial to compare the bioavailability of dihydroergotamine mesylate (DHE) following a single dose administration of INP104 (DHE administered by I123 Precision Olfactory Delivery (POD) Device Nasal Spray) to that…
- Trial name
- NCT03401346
- Testing
- INP104, Dihydroergotamine Mesylate (DHE), Migranal Nasal Spray
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
SARS-CoV-2 Acute Respiratory Disease
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID-19 affects several organs and systems at once.
- Trial name
- ETOC (NCT05133596)
- Testing
- Clinical examination, Blood collection, Olfactory evoked potentials
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Pasteur
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Epilepsy
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
- Trial name
- NCT02316847
- Testing
- diazepam nasal spray
- Where
- 33 sites in United States
- Volunteers
- 126 people
- Sponsor
- Acorda Therapeutics
Hyposmia
Study of CYR-064 Versus Placebo in Patients.
Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.
- Trial name
- NCT06019000
- Testing
- CYR-064
- Where
- 14 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Cyrano Therapeutics, Inc.
Substance Use Disorders, Opioid Use Disorder
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) device in substance use disorder (SUD)…
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder
- Trial name
- EDITOR (NCT06434818)
- Testing
- EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Evon Medics LLC
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals